Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ulotaront (Otsuka Holdings)
- Development stage
- Unknown
- Lead developer
- Otsuka Holdings
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ulotaront (also known as SEP-363856, SEP-383856, or SEP-856) is an investigational, orally active, first-in-class psychotropic small molecule under development for the treatment of schizophrenia, generalized anxiety disorder (GAD), and major depressive disorder (MDD). Unlike traditional antipsychotics that primarily act as dopamine D2 receptor antagonists, ulotaront functions as a dual agonist at the trace amine-associated receptor 1 (TAAR1) and the serotonin 5-HT1A receptor, with no direct binding to dopamine D2 or serotonin 5-HT2A receptors. It was discovered by Sunovion Pharmaceuticals (now Sumitomo Pharma America) in collaboration with PsychoGenics using the in vivo phenotypic SmartCube platform. In March 2024, Sumitomo Pharma transferred exclusive global development and commercialization rights for ulotaront to Otsuka Pharmaceutical.
- Other names
- ulotaront hydrochloride
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))TAAR1 (Trace amine-associated receptor 1)
Beyond the preview
Go deeper on ulotaront (Otsuka Holdings).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ulotaront (Otsuka Holdings).